Samsung Bioepis Launches Trastuzumab In Brazil
Ontruzant Rival To Herceptin Follows Brenzys Etanercept Biosimilar Launch Last Year
Samsung Bioepis has launched its Ontruzant rival to Herceptin in Brazil, claiming the first biosimilar trastuzumab to be supplied to the country’s public health system for early and metastatic HER2-overexpressing breast cancer.
